CAS 49763-96-4
:Stiripentol
- (1E)-1-(1,3-benzodioxol-5-yl)-4,4-dimethylpent-1-en-3-ol
- 1-(1,3-Benzodioxol-5-Yl)-4,4-Dimethylpent-1-En-3-Ol
- 1-(1,3-Benzodioxol-5-yl)-4,4-dimethyl-1-penten-3-ol
- 1-Penten-3-ol, 1-(1,3-benzodioxol-5-yl)-4,4-dimethyl-
- 256-480-9
- 4,4-Dimethyl-1-(3,4-methylenedioxyphenyl)-1-penten-3-ol
- Bcx 2600
- Diacomit
- Stiripentol
1-(Benzo[d][1,3]Dioxol-5-Yl)-4,4-Dimethylpent-1-En-3-Ol
CAS:1-(Benzo[d][1,3]Dioxol-5-Yl)-4,4-Dimethylpent-1-En-3-OlPurity:99%Molecular weight:234.29g/molStiripentol
CAS:Formula:C14H18O3Purity:≥ 98.0%Color and Shape:White to off-white powder or solidMolecular weight:234.29Stiripentol
CAS:Formula:C14H18O3Purity:>98.0%(GC)Color and Shape:White to Almost white powder to crystalMolecular weight:234.30Stiripentol
CAS:Stiripentol (BCX2600) (STP) is an anticonvulsant agent, which can inhibit N-demethylation of CLB to NCLB mediated by CYP3A4 (noncompetitively) and CYP2C19 (Formula:C14H18O3Purity:99.87% - >99.99%Color and Shape:White SolidMolecular weight:234.29Stiripentol
CAS:Controlled ProductApplications An epilepsy drug. It has been used as co-therapy for treatment of epilepsy. It inhibits the enzymes responsible for metabolism of other anti-convulsant agents.
References Laurie, D., et al.: J. Neurosci., 12, 4151 (1992), Smith, A., et al.: J. Pharmacol. Exp. Therap., 311, 601 (2004), Trojnar, M., et al.: Pharm. Rep., 57, 154 (2005), Drafts, B., et al.: J. Pharm. Exp. Ther., 318, 1094 (2006), Picton, A., et al.: Brain Res., 1165, 40 (2007),Formula:C14H18O3Color and Shape:Light Yellow SolidMolecular weight:234.294,4-Dimethyl-1-[(3,4-methylenedioxy)phenyl]-1-penten-3-ol
CAS:4,4-Dimethyl-1-[(3,4-methylenedioxy)phenyl]-1-penten-3-ol is a drug that has been used in the treatment of Dravet syndrome. This drug is also known as 3,4-methylenedioxyphenylacetone. It is a competitive inhibitor of the enzyme citrate synthase and inhibits the conversion of acetate to citrate. The effect of 4,4-dimethyl-1-[(3,4-methylenedioxy)phenyl]-1-penten-3-ol on sodium citrate concentrations is concentration dependent and results in an increase in plasma sodium concentrations with prolonged administration. Other drugs that are metabolized by the cytochrome P450 system may interact with 4,4-dimethyl-1-[(3,4 methylenedioxy)phenyl]-1 penten 3 ol and lead to increased levels of these drugs in the blood.
Formula:C14H18O3Purity:Min. 95%Color and Shape:White PowderMolecular weight:234.29 g/molStiripentol-13C3
CAS:Controlled ProductFormula:C3C11H18O3Color and Shape:NeatMolecular weight:237.269








